Itovebi
Roche’s Itovebi Demonstrates Significant Overall Survival Benefit in Advanced Breast Cancer Study
Itovebi, inavolisib, breast cancer, PIK3CA mutation, overall survival, INAVO120 study, Roche
FDA Approves Roche’s Itovebi, a PI3K Inhibitor for Advanced Breast Cancer Treatment
Roche, Itovebi, PI3K inhibitor, breast cancer, FDA approval, PIK3CA mutation, hormone receptor-positive, HER2-negative